Key result
Transcatheter mitral valve therapies offer low morbidity for treating mitral regurgitation in heart failure, but their derived benefit and priority remain to be investigated.
Why the study?
The derived benefit, priority of repair over replacement, and therapeutic role of transcatheter mitral valve therapies in secondary mitral regurgitation due to heart failure remain to be investigated.
Transcatheter mitral valve therapies offer a minimally invasive option for secondary mitral regurgitation in heart failure, though their definitive clinical benefit and optimal application require further investigation.
Answers are grounded in this paper and cite their sources.
May support further exploration in HF-MR; leaves open defined therapeutic roles pending larger trials.
Mitral valve regurgitation is detected in up to 75% of patients with heart failure. Interventional mitral valve therapies can be used to treat mitral regurgitation with very low morbidity and mortality rates and minimal invasiveness. Devices intended for the replacement of the mitral valve still require significant development and refinement before entering clinical practice on a large scale. The derived benefit of these therapies, the priority (repair over replacement) and the therapeutic role in patients with secondary mitral regurgitation due to heart failure remain to be investigated.
No takes yet. Share an insight, caveat, or question.
Treede et al. (2018) conducted a review in Heart failure with mitral valve regurgitation. Transcatheter mitral valve therapy was evaluated. Transcatheter mitral valve therapies offer low morbidity for treating mitral regurgitation in heart failure, but their derived benefit and priority remain to be investigated.
Synapse has enriched 10 related papers. Consider them for comparative context: